AR049319A1 - Derivados de 6-heteroarilfenantridinas - Google Patents
Derivados de 6-heteroarilfenantridinasInfo
- Publication number
- AR049319A1 AR049319A1 ARP050100780A AR049319A1 AR 049319 A1 AR049319 A1 AR 049319A1 AR P050100780 A ARP050100780 A AR P050100780A AR 049319 A1 AR049319 A1 AR 049319A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- completely
- substituted
- hydroxyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Abstract
Reivindicacion 1: Compuestos de la formula (1) en la cual: R1 es hidroxilo, alcoxi C1-4, cicloalcoxi C3-7, cicloalquil C3-7-metoxi, 2,2-difluoroetoxi, o alcoxi C1-4 completamente o predominantemente sustituido con F; R2 es hidroxilo, alcoxi C1-4, cicloalcoxi C3-7, cicloalquil-C3-7-metoxi, 2,2-difluoroetoxi, o alcoxi C1-4 completamente o predominantemente sustituido con F; o en donde R1 y R2 juntos son un grupo alquilendioxi C1-2; R3 es H o alquilo C1-4; R31 es H o alquilo C1-4; y, en una primera realizacion (realizacion a) de acuerdo con la presente, R4 es -O-R41, en donde R41 es H, alquilo C1-4, alcoxi C1-4-alquilo C1-4, hidroxialquilo C2-4, alquil C1-7-carbonilo o alquilo C1-4 completamente o predominantemente sustituido por F; y R5 es H o alquilo C1-4; o, en una segunda realizacion (realizacion b) de acuerdo con la presente, R4 es H o alquilo C1-4 y R5 es -O-R51, en donde R51 es H, alquilo C1-4, alcoxi C1-4-alquilo C1-4, hidroxialquilo C2-4, alquil C1-7-carbonilo o alquilo C1-4 completamente o predominantemente sustituido por F; Har está opcionalmente sustituido con R6 y/o R7 y/o R8, y es un radical heteroarilo insaturado o parcialmente saturado, monocíclico o bicíclico fusionado, de 5 a 10 miembros, que comprende 1 a 4 heteroátomos seleccionados independientemente del grupo que consiste de O, N y S, en donde R6 es halogeno, alquilo C1-4, alcoxi C1-4, alcoxi C1-4-alcoxi C2-4, alquiltio C1-4, sulfanilo, ciano, alcoxi C1-4-carbonilo, carboxilo, hidroxilo, oxo, -A- N(R61)R62, piridilo, o alquilo C1-4 completamente o parcialmente sustituido con F; en donde A es un enlace o alquileno C1-4; R61 es H o alquilo C1-4; R62 es H o alquilo C1-4; o R61 y R62 juntos y con la inclusion del átomo de N al cual están unidos, forman un anillo heterocíclico Het1, en donde Het1 está sustituido opcionalmente con R611 y es un radical de anillo heterocíclico monocíclico, saturado o insaturado, de 3 a 7 miembros, que comprende el átomo de N al cual están unidos R61 y R62, y opcionalmente 1 a 3 heteroátomos adicionales seleccionados independientemente del grupo que consiste de O, N y S, en donde R611 es alquilo C1-4; R7 es alquilo C1-4, alcoxi C1-4, alcoxi C1-4-alcoxi C2-4, alquiltio C1-4, sulfanilo, hidroxilo, oxo, amino o mono-o di-alquil C1-4- amino; R8 es halogeno, alquilo C1-4 o alcoxi C1-4; y las sales, los N-oxidos y las sales de los N-oxidos de estos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04004973 | 2004-03-03 | ||
EP04106359 | 2004-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049319A1 true AR049319A1 (es) | 2006-07-19 |
Family
ID=34921303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050100780 AR049319A1 (es) | 2004-03-03 | 2005-03-02 | Derivados de 6-heteroarilfenantridinas |
Country Status (29)
Country | Link |
---|---|
US (8) | US8003798B2 (es) |
EP (2) | EP1723135B1 (es) |
JP (2) | JP4801039B2 (es) |
KR (2) | KR101152439B1 (es) |
CN (6) | CN1922170A (es) |
AR (1) | AR049319A1 (es) |
AU (1) | AU2005219576B2 (es) |
BR (1) | BRPI0508321B1 (es) |
CA (1) | CA2557752C (es) |
CO (1) | CO5700749A2 (es) |
CY (2) | CY1114319T1 (es) |
DK (2) | DK1723135T5 (es) |
EA (2) | EA017282B1 (es) |
ES (2) | ES2505473T3 (es) |
HK (4) | HK1207635A1 (es) |
HR (2) | HRP20130828T1 (es) |
IL (2) | IL177073A (es) |
ME (1) | ME01955B (es) |
MX (2) | MX341474B (es) |
NO (2) | NO336538B1 (es) |
NZ (1) | NZ549108A (es) |
PL (2) | PL2589599T4 (es) |
PT (2) | PT1723135E (es) |
RS (2) | RS52916B (es) |
SG (1) | SG182194A1 (es) |
SI (2) | SI2589599T1 (es) |
TW (2) | TWI372750B (es) |
WO (1) | WO2005085225A1 (es) |
ZA (1) | ZA200606176B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE353217T1 (de) | 2002-08-29 | 2007-02-15 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
JP4728259B2 (ja) | 2004-02-18 | 2011-07-20 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 効果的なホスホジエステラーゼ(pde)4インヒビターとしての新規のグアニジニル置換されたヒドロキシ−6−フェニルフェナントリジン |
RS52916B (en) | 2004-03-03 | 2014-02-28 | Takeda Gmbh | NEW HYDROXY-6-HETEROARYLPHENANTRIDINES AND THEIR USE AS PDE4 INHIBITORS |
WO2006082185A1 (en) | 2005-02-01 | 2006-08-10 | Nycomed Gmbh | Novel 6-pyridylphenanthridines |
EP1856092A1 (en) * | 2005-03-02 | 2007-11-21 | Nycomed GmbH | 6-heteroaryl-1,2,3,4,4a,10b-hexahydro-phenanthridines as pde-4 inhibitors for the treatment of inflammatory disorders |
NZ589278A (en) * | 2005-03-02 | 2012-04-27 | Nycomed Gmbh | Selected salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
EP2063890A1 (en) * | 2006-09-07 | 2009-06-03 | Nycomed GmbH | Combination treatment for diabetes mellitus |
KR101599661B1 (ko) * | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
WO2009025823A1 (en) * | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2009109525A1 (en) * | 2008-03-03 | 2009-09-11 | Nycomed Gmbh | Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease |
AR074318A1 (es) * | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
CA2936332A1 (en) * | 2014-01-22 | 2015-07-30 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier) |
CN103936661B (zh) * | 2014-04-04 | 2016-08-24 | 常州大学 | 一种6-烷基菲啶衍生物的合成方法 |
JP2018521077A (ja) * | 2015-07-29 | 2018-08-02 | タケダ ゲー・エム・ベー・ハーTakeda GmbH | 糖尿病性腎症を治療するためのpde4阻害剤 |
CN110099686B (zh) * | 2016-08-26 | 2022-04-15 | 武田药品工业株式会社 | 非酒精性脂肪性肝病的治疗 |
AU2018234059A1 (en) | 2017-03-16 | 2019-10-31 | Takeda Gmbh | Treatment of idiopathic pulmonary fibrosis |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
WO2020113088A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
TWI785816B (zh) * | 2019-08-30 | 2022-12-01 | 國立陽明交通大學 | 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法 |
TWI753296B (zh) * | 2019-08-30 | 2022-01-21 | 國立陽明交通大學 | 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027055D0 (en) * | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
CA2165192C (en) | 1993-07-02 | 2001-04-24 | Hermann Amschler | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
SI0882021T1 (en) | 1996-01-31 | 2003-10-31 | Altana Pharma Ag | New phenanthridines |
ATE224386T1 (de) | 1996-03-26 | 2002-10-15 | Altana Pharma Ag | Neue in 6-position substituierte phenanthridine |
US6127378A (en) | 1996-03-26 | 2000-10-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridines substituted in the 6 position |
JPH1020274A (ja) * | 1996-07-05 | 1998-01-23 | Fujitsu Ltd | 液晶表示駆動回路及び液晶表示装置 |
NZ334976A (en) | 1996-11-11 | 2000-10-27 | Byk Gulden Lomberg Chem Fab | Benzonaphthyridine derivatives and their use for treating airway disorders and dermatoses |
AU6825898A (en) | 1997-03-07 | 1998-09-29 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel tetrazoles |
US6384047B1 (en) | 1997-06-03 | 2002-05-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine |
JP2001510827A (ja) | 1997-07-25 | 2001-08-07 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 置換6−フェニルフェナントリジン |
PL190685B1 (pl) | 1997-07-25 | 2005-12-30 | Altana Pharma Ag | Nowe pochodne tetrazolu, środek farmaceutyczny oraz zastosowanie |
DK1000034T3 (da) | 1997-07-25 | 2003-01-27 | Altana Pharma Ag | Substituerede 6-alkylphenanthridiner |
ID24942A (id) * | 1997-11-04 | 2000-08-31 | Pfizer Prod Inc | Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4 |
PT1075477E (pt) | 1998-05-05 | 2003-07-31 | Altana Pharma Ag | Novos n-oxidos de benzonaftiridina |
CA2342245A1 (en) | 1998-08-31 | 2000-03-09 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity |
EP1163226B1 (en) | 1999-01-15 | 2007-03-14 | ALTANA Pharma AG | Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
ES2242594T3 (es) | 1999-01-15 | 2005-11-16 | Altana Pharma Ag | N-oxidos de fenantridinas con una acitvidad inhidora de pde-iv. |
CN1152864C (zh) | 1999-01-15 | 2004-06-09 | 奥坦纳医药公司 | 具有pde-iv抑制活性的苯基菲啶类化合物 |
AU2289400A (en) * | 1999-01-15 | 2000-08-01 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 6-arylphenanthridines with pde-iv inhibiting activity |
CA2359449A1 (en) * | 1999-01-15 | 2000-07-20 | Beate Gutterer | Phenanthridine-n-oxides with pde-iv inhibiting activity |
CN1146562C (zh) * | 1999-10-25 | 2004-04-21 | 奥坦纳医药公司 | 作为pde4抑制剂的四氢噻喃2,3-二氮杂萘酮类衍生物 |
AU782908B2 (en) | 2000-01-11 | 2005-09-08 | Altana Pharma Ag | Phenanthridine-N-oxides |
CA2404226A1 (en) | 2000-03-23 | 2001-09-27 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivatives, process for producing the same and use thereof |
WO2002006238A1 (en) | 2000-07-14 | 2002-01-24 | Altana Pharma Ag | Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines |
WO2002006270A1 (en) | 2000-07-14 | 2002-01-24 | Altana Pharma Ag | Novel 6-heteroarylphenanthridines |
AU2001281965A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Novel 6-phenylphenanthridines |
ES2236504T3 (es) | 2001-02-21 | 2005-07-16 | Altana Pharma Ag | 6-fenilbenzonaftiridinas. |
RS20050117A (en) | 2002-08-17 | 2007-06-04 | Altana Pharma Ag., | Novel benzonaphthyridines |
PL374014A1 (en) * | 2002-08-17 | 2005-09-19 | Altana Pharma Ag | Novel phenanthridines having pde 3/4 inhibiting properties |
ATE353217T1 (de) * | 2002-08-29 | 2007-02-15 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
JP4587294B2 (ja) * | 2002-08-29 | 2010-11-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pde4インヒビターとしての2−ヒドロキシ−6−フェニルフェナントリジン |
RU2247262C2 (ru) | 2003-05-19 | 2005-02-27 | Федеральное государственное унитарное предприятие Российский Федеральный Ядерный Центр-Всероссийский Научно-исследовательский институт технической физики им. акад. Е.И. Забабахина (РФЯЦ- ВНИИТФ) | Плунжерный насос сверхвысокого давления |
JP4728259B2 (ja) * | 2004-02-18 | 2011-07-20 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 効果的なホスホジエステラーゼ(pde)4インヒビターとしての新規のグアニジニル置換されたヒドロキシ−6−フェニルフェナントリジン |
AR049419A1 (es) | 2004-03-03 | 2006-08-02 | Altana Pharma Ag | Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo |
RS52916B (en) | 2004-03-03 | 2014-02-28 | Takeda Gmbh | NEW HYDROXY-6-HETEROARYLPHENANTRIDINES AND THEIR USE AS PDE4 INHIBITORS |
CA2558375A1 (en) * | 2004-03-09 | 2005-09-15 | Altana Pharma Ag | Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
WO2005087744A1 (en) | 2004-03-10 | 2005-09-22 | Altana Pharma Ag | Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
NZ549254A (en) * | 2004-03-10 | 2010-06-25 | Nycomed Gmbh | Amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors |
JP2007527898A (ja) * | 2004-03-10 | 2007-10-04 | アルタナ ファルマ アクチエンゲゼルシャフト | ジフルオロエトキシ置換された新規のヒドロキシ−6−フェニルフェナントリジン及びpde4インヒビターとしてのそれらの使用 |
NZ589278A (en) | 2005-03-02 | 2012-04-27 | Nycomed Gmbh | Selected salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
-
2005
- 2005-03-02 RS RS20130349A patent/RS52916B/en unknown
- 2005-03-02 WO PCT/EP2005/050931 patent/WO2005085225A1/en active Application Filing
- 2005-03-02 CN CNA2005800057687A patent/CN1922170A/zh active Pending
- 2005-03-02 JP JP2007501289A patent/JP4801039B2/ja not_active Expired - Fee Related
- 2005-03-02 CN CN201510101394.4A patent/CN104761545A/zh active Pending
- 2005-03-02 EP EP05716889.0A patent/EP1723135B1/en active Active
- 2005-03-02 PT PT57168890T patent/PT1723135E/pt unknown
- 2005-03-02 SG SG2012043295A patent/SG182194A1/en unknown
- 2005-03-02 PL PL12196702T patent/PL2589599T4/pl unknown
- 2005-03-02 EP EP20120196702 patent/EP2589599B1/en active Active
- 2005-03-02 CA CA2557752A patent/CA2557752C/en not_active Expired - Fee Related
- 2005-03-02 KR KR1020067019892A patent/KR101152439B1/ko not_active IP Right Cessation
- 2005-03-02 EA EA201000494A patent/EA017282B1/ru not_active IP Right Cessation
- 2005-03-02 BR BRPI0508321-4A patent/BRPI0508321B1/pt not_active IP Right Cessation
- 2005-03-02 CN CN201510101203.4A patent/CN104803974A/zh active Pending
- 2005-03-02 MX MX2011010146A patent/MX341474B/es unknown
- 2005-03-02 PL PL05716889T patent/PL1723135T3/pl unknown
- 2005-03-02 MX MXPA06009695A patent/MXPA06009695A/es active IP Right Grant
- 2005-03-02 CN CN201510100429.2A patent/CN104817534A/zh active Pending
- 2005-03-02 ES ES12196702.0T patent/ES2505473T3/es active Active
- 2005-03-02 AR ARP050100780 patent/AR049319A1/es not_active Application Discontinuation
- 2005-03-02 PT PT12196702T patent/PT2589599E/pt unknown
- 2005-03-02 SI SI200531890T patent/SI2589599T1/sl unknown
- 2005-03-02 EA EA200601568A patent/EA014155B1/ru not_active IP Right Cessation
- 2005-03-02 DK DK05716889.0T patent/DK1723135T5/da active
- 2005-03-02 ME MEP-2014-113A patent/ME01955B/me unknown
- 2005-03-02 CN CN201510100383.4A patent/CN104803973A/zh active Pending
- 2005-03-02 KR KR1020117030419A patent/KR101152488B1/ko not_active IP Right Cessation
- 2005-03-02 SI SI200531772T patent/SI1723135T1/sl unknown
- 2005-03-02 DK DK12196702T patent/DK2589599T3/da active
- 2005-03-02 AU AU2005219576A patent/AU2005219576B2/en not_active Ceased
- 2005-03-02 CN CN2011101613875A patent/CN102295634A/zh active Pending
- 2005-03-02 US US10/590,803 patent/US8003798B2/en active Active
- 2005-03-02 RS RSP20140498 patent/RS53543B1/en unknown
- 2005-03-02 NZ NZ549108A patent/NZ549108A/en unknown
- 2005-03-02 ES ES05716889T patent/ES2427256T3/es active Active
- 2005-03-03 TW TW094106493A patent/TWI372750B/zh not_active IP Right Cessation
- 2005-03-03 TW TW100110218A patent/TWI404704B/zh not_active IP Right Cessation
-
2006
- 2006-07-25 IL IL177073A patent/IL177073A/en not_active IP Right Cessation
- 2006-07-26 ZA ZA200606176A patent/ZA200606176B/xx unknown
- 2006-07-28 CO CO06074146A patent/CO5700749A2/es active IP Right Grant
- 2006-09-19 NO NO20064221A patent/NO336538B1/no not_active IP Right Cessation
-
2011
- 2011-01-21 JP JP2011011310A patent/JP5193320B2/ja active Active
- 2011-05-19 US US13/111,524 patent/US8318944B2/en not_active Expired - Fee Related
- 2011-05-19 US US13/111,544 patent/US8324391B2/en active Active
-
2012
- 2012-08-06 IL IL221323A patent/IL221323A0/en not_active IP Right Cessation
- 2012-10-26 US US13/661,897 patent/US8455653B2/en not_active Expired - Fee Related
-
2013
- 2013-04-30 US US13/873,670 patent/US8883818B2/en not_active Expired - Fee Related
- 2013-09-05 HR HRP20130828TT patent/HRP20130828T1/hr unknown
- 2013-09-09 CY CY20131100770T patent/CY1114319T1/el unknown
-
2014
- 2014-09-08 CY CY20141100722T patent/CY1115536T1/el unknown
- 2014-09-17 HR HRP20140892TT patent/HRP20140892T1/hr unknown
- 2014-10-07 US US14/508,077 patent/US9149479B2/en not_active Expired - Fee Related
- 2014-12-18 NO NO20141541A patent/NO338326B1/no not_active IP Right Cessation
-
2015
- 2015-08-25 US US14/834,709 patent/US9387205B2/en active Active
- 2015-08-26 HK HK15108262.7A patent/HK1207635A1/xx unknown
- 2015-09-16 HK HK15109032.4A patent/HK1208447A1/xx unknown
- 2015-09-30 HK HK15109596.2A patent/HK1208865A1/xx unknown
-
2016
- 2016-01-18 HK HK16100490.7A patent/HK1214812A1/zh unknown
- 2016-06-10 US US15/179,268 patent/US9962377B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049319A1 (es) | Derivados de 6-heteroarilfenantridinas | |
AR050932A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
AR050365A1 (es) | Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos. | |
PE20181487A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
PE20220141A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
AR051413A1 (es) | Piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) | |
AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
AR072052A1 (es) | Derivados de indano como reguladores del receptor ampa | |
AR068496A1 (es) | Piperidinas sustituidas, una composicion farmaceutica que las comprende y su uso para el tratamiento de enfermedades mediadas por la modulacion de la actividad de gpr119. | |
PE20170321A1 (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos | |
AR069334A1 (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana | |
UY28758A1 (es) | Inhibidores de polimerasa viral | |
PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
AR054789A1 (es) | Antagonistas del receptor 1 de triazolopiridina canabinoide | |
AR054799A1 (es) | Derivados de oxindol | |
PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
AR058896A1 (es) | Isoxazolinas para controlar plagas de invertebrados | |
CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR080688A1 (es) | Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina | |
AR058984A1 (es) | Derivados de ciclohexil piperazinil metanona | |
AR060405A1 (es) | Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed, e.g., due to non-payment of fee |